310 related articles for article (PubMed ID: 31394796)
1. CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs.
Sulaiman A; McGarry S; Han X; Liu S; Wang L
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31394796
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
3. Clinically Translatable Approaches of Inhibiting TGF-β to Target Cancer Stem Cells in TNBC.
Sulaiman A; McGarry S; Chilumula SC; Kandunuri R; Vinod V
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680503
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes
Olsson M; Larsson P; Johansson J; Sah VR; Parris TZ
Front Cell Dev Biol; 2023; 11():1237673. PubMed ID: 37771376
[No Abstract] [Full Text] [Related]
5. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
[TBL] [Abstract][Full Text] [Related]
6. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
[TBL] [Abstract][Full Text] [Related]
8. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
10. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.
Hossain F; Sorrentino C; Ucar DA; Peng Y; Matossian M; Wyczechowska D; Crabtree J; Zabaleta J; Morello S; Del Valle L; Burow M; Collins-Burow B; Pannuti A; Minter LM; Golde TE; Osborne BA; Miele L
Front Oncol; 2018; 8():575. PubMed ID: 30564555
[TBL] [Abstract][Full Text] [Related]
11. At the Intersection of Cardiology and Oncology: TGFβ as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy.
Sulaiman A; Chambers J; Chilumula SC; Vinod V; Kandunuri R; McGarry S; Kim S
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326728
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H; Srour EF; Badve S
Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
[TBL] [Abstract][Full Text] [Related]
13. Targeting Cancer Stem Cells in Triple-Negative Breast Cancer.
Park SY; Choi JH; Nam JS
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31324052
[TBL] [Abstract][Full Text] [Related]
14. Development of a Fluorescent Reporter System to Delineate Cancer Stem Cells in Triple-Negative Breast Cancer.
Thiagarajan PS; Hitomi M; Hale JS; Alvarado AG; Otvos B; Sinyuk M; Stoltz K; Wiechert A; Mulkearns-Hubert E; Jarrar A; Zheng Q; Thomas D; Egelhoff T; Rich JN; Liu H; Lathia JD; Reizes O
Stem Cells; 2015 Jul; 33(7):2114-2125. PubMed ID: 25827713
[TBL] [Abstract][Full Text] [Related]
15. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation.
Moreira MP; Brayner FA; Alves LC; Cassali GD; Silva LM
Eur Biophys J; 2019 Oct; 48(7):673-684. PubMed ID: 31485678
[TBL] [Abstract][Full Text] [Related]
17. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
[TBL] [Abstract][Full Text] [Related]
18. The Flick of a Switch: Conferring Survival Advantage to Breast Cancer Stem Cells Through Metabolic Plasticity.
Walsh HR; Cruickshank BM; Brown JM; Marcato P
Front Oncol; 2019; 9():753. PubMed ID: 31552162
[TBL] [Abstract][Full Text] [Related]
19. Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence.
Petrella PE; Chen JW; Ravelo GO; Cosgrove BD
bioRxiv; 2024 Apr; ():. PubMed ID: 38746322
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem-like cells directly participate in vasculogenic mimicry channels in triple-negative breast cancer.
Sun H; Yao N; Cheng S; Li L; Liu S; Yang Z; Shang G; Zhang D; Yao Z
Cancer Biol Med; 2019 May; 16(2):299-311. PubMed ID: 31516750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
